OBJECTIVES: The aim of this study was to collect comparable and reliable data on therapy of cardiovascular disease in Slovakia during the period 1997 – 2006. The special interest was paid to the utilisation of antihypertensive medication. METHODS: For 1997 - 2006, the data about consumption of drugs for treatment of cardiovascular disease were collected, in accordance with the Anatomic Therapeutic Chemical classification (ATC: C01- C10) and Defined Daily Dose (DDD) measurement unit. Data of wholesalers, who are legally obliged provide this information to the Slovak Institute for Drug Control, was used for the analysis. RESULTS: A significant increase in the consumption of drugs for cardiovascular disease (in 1997 (238.06), in 2001 (329.27) and in 2006 (450.08) in term of DDD/1000/day can be seen from this analysis. The results show that the consumption (in term of DDD/1000/day) of ß-blockers was (in 1997 (28.88), in 2001 (36.36) and in 2006 (45.13), ACE inhibitors (in 1997 (32.68), in 2001 (70.51) and in 2006 (115.52), Ca-blockers (in 1997 (29.60), in 2001 (46.09) and in 2006 (71.09), diuretics (in 1997 (23.88), in 2001 (30.16) and in 2006 (38.23), peripheral vasodilators (in 1997 (19.10), in 2001 (21.36) and in 2006 (14.58), vasoprotectives (in 1997 (34.99), in 2001 (37.10) and in 2006 (35.63), serum lipid reducing agents (in 1997 (6.68), in 2001 (16.64) and in 2006 (48.08). In financial terms, the consumption of ß-blockers in 1997 (5,596,000 €) and 2006 (12,740,000 €), ACE inhibitors in 1997 (11,974,000 €) and 2006 (42,671,000 €), Ca-blockers in 1997 (8,690,000 €) and 2006 (18,066,000 €), diuretics in 1997 (1,566,000 €) and 2006 (3,711,000 €) can be seen from this study. CONCLUSION: Usage of generic drugs for the treatment of cardiovascular disease brought about a dramatic increase in drug consumptions and the financial expenditures for health insurance funds have been remained under control.